Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis

British Journal of Pharmacology

Volumn 152, Issue 7, 2007, Pages 1102-1110

  Moro, C ^a,b   Klimcakova, E ^a,b   Lafontan, M ^a,b   Berlan, M ^a,b   Galitzky, J ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Atrial natriuretic peptide; cGMP signalling; Lipolysis; Phosphodiesterase

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; MEMBRANE METALLOENDOPEPTIDASE; N CYCLOHEXYL 4 (1,2 DIHYDRO 2 OXO 6 QUINOLYLOXY) N (2 HYDROXYETHYL)BUTYRAMIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VA; SILDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL; ZAPRINAST;

ADIPOCYTE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIPOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

1-METHYL-3-ISOBUTYLXANTHINE; ADIPOCYTES; ADULT; ATRIAL NATRIURETIC FACTOR; BLOTTING, WESTERN; CELLS, CULTURED; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KINETICS; LIPOLYSIS; NEPRILYSIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIORPHAN; TIME FACTORS;

EID: 36448947672     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707485     Document Type: Article

References (39)

1. Arner P (2005). Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab 19: 471-482.
2. Arvidsson E, Viguerie N, Andersson I, Verdich C, Langin D, Arner P (2004). Effects of different hypocaloric diets on protein secretion from adipose tissue of obese women. Diabetes 53: 1966-1971.
3. Beavo JA (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75: 725-748.
4. Bradley DC, Kaslow HR (1989). Radiometric assays for glycerol, glucose, and glycogen. Anal Biochem 180: 11-16.
5. Corbin JD, Francis SH (2002). Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56: 453-459.
6. Corbin JD, Francis SH, Webb DJ (2002). Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 60: 4-11.
7. Degerman E, Smith CJ, Tornqvist H, Vasta V, Belfrage P, Manganiello VC (1990). Evidence that insulin and isoprenaline activate the cGMP-inhibited low-Km cAMP phosphodiesterase in rat fat cells by phosphorylation. Proc Natl Acad Sci USA 87: 533-537.
8. Fan D, Bryan PM, Antos LK, Potthast RJ, Potter LR (2004). Downregulation does not mediate natriuretic peptide-dependent desensitization of NPR-A or NPR-B: guanylyl cyclase-linked natriuretic peptide receptors do not internalize. Mol Pharmacol 67: 174-183.
9. Hauner H, Entenmann G (1991). Regional variation of adipose differentiation in cultured stromal-vascular cells from the abdominal and femoral adipose tissue of obese women. Int J Obes 15: 121-126.
10. Knecht M, Pagel I, Langenickel T, Philipp S, Scheuermann-Freestone M, Willnow T et al. (2002). Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci 71: 2701-2712.
11. Lafontan M, Berlan M (1993). Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 34: 1057-1091.
12. Langin D (2006). Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol Res 53: 482-491.
13. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL et al. (1998). Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 216: 139-147.
14. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR et al. (2003). Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 64: 533-546.
15. Mishima T, Tanimura M, Suzuki G, Todor A, Sharov VG, Tanhehco EJ et al. (2002). Effects of chronic neutral endopeptidase inhibition on the progression of left ventricular dysfunction and remodeling in dogs with moderate heart failure. Cardiovasc Drugs Ther 16: 209-214.
16. Moro C, Crampes F, Sengenes C, De Glisezinski I, Galitzky J, Thalamas C et al. (2004a). Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans. FASEB J 18: 908-910.
17. Moro C, Galitzky J, Sengenes C, Crampes F, Lafontan M, Berlan M (2004b). Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. J Pharmacol Exp Ther 308: 984-992.
18. Moro C, Polak J, Hejnova J, Klimcakova E, Crampes F, Stich V et al. (2006). Atrial natriuretic peptide stimulates lipid mobilization during repeated bouts of endurance exercise. Am J Physiol Endocrinol Metab 290: E864-E869.
19. Moro C, Polak J, Richterova B, Sengenes C, Pelikanova T, Galitzky J et al. (2005). Differential regulation of atrial natriuretic peptide-and adrenergic receptor-dependent lipolytic pathways in human adipose tissue. Metabolism 54: 122-131.
20. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, Koesling D (2003). Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol 160: 719-727.
21. Mullershausen F, Russwurm M, Thompson WJ, Liu L, Koesling D, Friebe A (2001). Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J Cell Biol 155: 271-278.
22. Murthy KS (2001). Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle. Biochem J 360: 199-208.
23. Potter LR, Garbers DL (1992). Dephosphorylation of the guanylyl cyclase-A receptor causes desensitization. J Biol Chem 267: 14531-14534.
24. Potter LR, Abbey-Hosch S, Dickey DM (2006). Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 27: 47-72.
25. Potthast R, Potter LR (2005). Phosphorylation-dependent regulation of the guanylyl cyclase-linked natriuretic peptide receptors. Peptides 26: 1001-1008.
26. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA (2002). Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 277: 3310-3317.
27. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA (2003a). PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 22: 469-478.
28. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003b). Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93: 280-291.
29. Sarzani R, Dessi-Fulgheri P, Paci V, Espinosa E, Rappelli A (1996). Expression of natriuretic peptide receptors in human adipose tissue and other tissues. J Endocrinol Invest 19: 581-585.
30. Sarzani R, Strazzullo P, Salvi F, Iacone R, Pietrucci F, Siani A et al. (2004). Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. Obes Res 12: 351-356.
31. Sengenès C, Berlan M, de Glisezinski I, Lafontan M, Galitzky J (2000). Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 14: 1345-1351.
32. Sengenès C, Bouloumié A, Hauner H, Berlan M, Busse R, Lafontan M et al. (2003). Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem 278: 48617-48626.
33. Sengenès C, Zakaroff-Girard A, Moulin A, Berlan M, Bouloumié A, Lafontan M et al. (2002). Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. Am J Physiol Regul Integr Comp Physiol 283: R257-R265.
34. Soderling SH, Bayuga SJ, Beavo JA (1998). Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 273: 15553-15558.
35. Soderling SH, Beavo JA (2000). Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12: 174-179.
36. Turner AJ (2003). Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries. Biochem Soc Trans 31: 723-727.
37. Walter M, Unwin R, Nortier J, Deschodt-Lanckman M (1997). Enhancing endogenous effects of natriuretic peptides: inhibitors of neutral endopeptidase (EC.3.4.24.11) and phosphodiesterase. Curr Opin Nephrol Hypertens 6: 468-473.
38. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW et al. (2004). Impact of obesity on plasma natriuretic peptide levels. Circulation 109: 594-600.
39. Yanaka N, Kotera J, Ohtsuka A, Akatsuka H, Imai Y, Michibata H et al. (1998). Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem 255: 391-399.